U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07400458) titled 'Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration' on May 09, 2024.
Brief Summary: This Long-term follow-up is designed to evaluate the safety of patient with Acute Myocardial Infarction who had administered Hearticellgram-AMI.
Study Start Date: March 03, 2022
Study Type: INTERVENTIONAL
Condition:
Acute Myocardial Infarction
Intervention:
BIOLOGICAL: Hearticellgram-AMI
Patients who had administered Hearticellgram-AMI.
Recruitment Status: RECRUITING
Sponsor: Pharmicell Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....